Efficient inhibition of fusion inhibitor HY3000 peptide to SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variants
Lili Wu(Chinese Academy of Sciences), George F. Gao(Chinese Academy of Sciences), Guizhen Wu(Chinese Center For Disease Control and Prevention), Anqi Zheng(Peking University), Yangming Tang, Xiaoyun Wang(Nanjing Tech University), Gao Yue(Chinese Academy of Sciences), Qihui Wang(Shanxi Agricultural University), Wenwen Lei(China Pharmaceutical University)
Cited by 1
Related Papers
A Novel Coronavirus from Patients with Pneumonia in China, 2019
|New England Journal of Medicine|2020|30.5k
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
|The Lancet|2020|12.6k
Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus
|New England Journal of Medicine|2013|2.4k
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
|Nature|2020|1.2k